Abstract
By using DNA vaccines, it may be possible to give increased protection against influenza than can currently be achieved. DNA vaccines are a relatively new concept and their potential has been demonstrated in preclinical studies. Another recent innovation is the use of recombinant BCG (rBCG) as a vaccine vehicle. rBCG has the advantage of being a strong immunostimulant, and, when applied to mucosal surfaces, elicits both systemic and mucosal immune responses. These 2 developments in vaccine technology were discussed at the IBC 2nd Annual Conference on ‘New Advances in Vaccine Technologies and Applications’ [Bethesda, US; February 1995].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
